Dr. Sequist Discusses the IMPRESS Trial
Lecia V. Sequist, MD, MPH, associate professor of medicine, Massachusetts General Hospital, discusses the IMPRESS trial, which was presented at the 2015 World Conference on Lung Cancer.
Sequist says the results were unexpected, since since continued gefitinib with chemotherapy were thought to have a stronger benefit. However, the results showed no difference. Tony Mok, MD, who presented the study, found that patients with a T790M resistance mutation did not benefit from continuing gefitinib. Those without the mutation showed an improved progression-free survival.
Lecia V. Sequist, MD, MPH, associate professor of medicine, Massachusetts General Hospital, discusses the IMPRESS trial, which was presented at the 2015 World Conference on Lung Cancer. This was a randomized study where patients were given front-line gefitinib. At the time of progression, they were randomized to either continue gefitinib with chemotherapy or to stop gefitinib and receive placebo with chemotherapy.
Adaptive NSCLC Trial Misses Target Efficacy, Reaches Clinical Benefit in Some Patients
September 16th 2024The PIONeeR trial, evaluating combinations of immunotherapy drugs for advanced NSCLC, identified durvalumab plus ceralasertib as a promising treatment option, demonstrating long-term clinical benefit in some patients.
Read More
Adagrasib Outperforms Docetaxel for Pretreated KRAS G12C-Mutant Non-Small Cell Lung Cancer
September 15th 2024Adagrasib demonstrated superior outcomes to docetaxel in patients with previously treated KRAS G12C-mutated non-small cell lung cancer, even among those with baseline brain metastases.
Read More
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
September 14th 2024Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
Read More
